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There is an urgent need for new therapeutics for the 
treatment of aggressive and metastatic refractory human 
non-small–cell lung cancer (NSCLC). Antiangiogenesis 
therapy and chemotherapy are the two major treat-
ment options. Unfortunately, both types of therapies 
when used individually have their disadvantages. Inte-
grating antiangiogenesis therapy with chemotherapy is 
expected to target the tumor’s vascular endothelial cells 
and the tumor cells simultaneously. In this study, we 
coformulated Vascular endothelial growth factor (VEGF) 
siRNA targeting VEGFs and gemcitabine monophos-
phate (GMP) into a single cell-specific,  targeted lipid/
calcium/phosphate (LCP) nanoparticle formulation. 
Antitumor effect of the combination therapy using LCP 
loaded with both VEGF siRNA and GMP was evaluated 
in both subcutaneous and orthotopic xenograft models 
of NSCLC with systemic administration. The improved 
therapeutic response, as compared with either VEGF 
siRNA or GMP therapy alone, was supported by the 
observation of 30–40% induction of tumor cell apop-
tosis, eightfold reduction of tumor cell proliferation 
and significant decrease of tumor microvessel density 
(MVD). The combination therapy led to dramatic inhibi-
tion of tumor growth, with little in vivo toxicity. In addi-
tion, the current studies demonstrated the possibility of 
incorporating multiple nucleic acid molecules and phos-
phorylated small-molecule drugs, targeting to different 
pathways, into a single nanoparticle formulation for pro-
found therapeutic effect.
Received 11 March 2013; accepted 3 May 2013; advance online  
publication 18 June 2013. doi:10.1038/mt.2013.120
INTRODUCTION
The combination of chemotherapy and gene therapy could greatly 
increase their therapeutic efficacy in the treatment of many human 
diseases. The drawbacks associated with standard chemotherapy 
regimens can be alleviated by the addition of gene therapy to the 
treatment plan.1 Furthermore, the efficacy of gene therapy can be 
bolstered by chemo-agents whose effects are often more potent and 
widespread. This increase in efficacy could be particularly important 
in the treatment of aggressive human cancers whose progression and 
invasion involves a variety of physiological or pathological factors, 
such as non-small–cell lung cancer (NSCLC).
Antiangiogenesis therapy and chemotherapy are important 
treatment regimens for NSCLC. Vascular endothelial growth fac-
tor (VEGF) is overexpressed in malignant tumors and is a major 
driver of tumor angiogenesis. Blocking the VEGF signaling path-
way can reduce tumor-associated angiogenesis and blood  vessel–
dependent metastasis.2,3 VEGF-receptor (VEGFR) inhibitors, 
such as small-molecule inhibitors, anti-VEGF monoclonal anti-
bodies, and aptamers that strongly antagonize the VEGF-VEGFR 
binding with high specificity, have been developed.4–6 However, 
the efficacy of these inhibitors is often limited by unfavorable 
pharmacokinetics, low tumor accumulation, and undesired 
interaction with the immune system. Additional adverse effects 
also compromise the therapeutic response in patients7,8 siRNA 
specific to VEGF, if properly delivered to the tumor cells, may 
overcome some shortcomings of the traditional drugs, especially 
when it is codelivered with an efficient chemodrug. Gemcitabine 
(2′,2′-difluoro 2′-deoxycytidine) (Gem) is a nucleoside analogue 
widely used as the first-line chemotherapy of advanced NSCLC. 
Gem relies on nucleoside transporters to enter into cells, sequen-
tially phosphorylated by deoxycytidine kinase that forms mono-, 
di-, and triphosphate derivatives. The addition of the first phos-
phate group to become gemcitabine monophosphate (GMP) is 
the rate-limiting step.9 5′-Triphosphate derivative of Gem is then 
incorporated into the DNA strand where it inhibits replication by 
terminating the DNA chain elongation.9
To combine the therapeutic advantages of VEGF siRNA and 
Gem, while also avoiding their delivery roadblocks, we entrapped 
both VEGF siRNA and GMP into a single lipid/calcium/phosphate 
(LCP) nanoparticle formulation. Our aim was to apply multiple 
tumor-killing steps to programmatically inhibit tumor growth 
and eventually eradicate tumor progression. The small molecule 
ligand, anisamide (AA), was modified to the LCP surface to spe-
cifically target the sigma receptors that are overexpressed in many 
human cancer cells. The rational design of LCP nanoplatform lies 
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in the fact that calcium ions can precipitate both siRNA and GMP. 
Thus, an antiangiogenic and a chemo-agents can be simultane-
ously delivered to the tumor cells to block different mechanisms 
of tumor cell proliferation (Figure 1a).10 LCPs entrapping only 
VEGF siRNA (VEGF-LCP-AA) and LCPs entrapping only GMP 
(GMP-LCP-AA) were prepared and tested separately to compare 
with the combination therapy. Cytidine monophosphate (CMP), 
having a chemical structure similar to GMP, but without any 
cytotoxic effect, serves as the surrogate for GMP. LCPs entrapping 
both CMP and control siRNA ((CMP+Con)-LCP-AA) were used 
as control nanoparticles.
RESULTS
Characterization of drug-loaded LCPs
LCP is a membrane/core type nanoparticle. It is composed of a 
solid calcium phosphate precipitate core coated with a single lipid 
Figure 1 Schematic illustration of (a) the in vivo codelivery mechanism and (b) the preparation procedure of GMP- and/or VEGF siRNA–loaded 
LCP formulations. AA, anisamide; EPR, enhanced permeability and retention; GMP, gemcitabine monophosphate; LCP, lipid/calcium/phosphate.
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bilayer. The lipid membrane wrapping around the core is modified 
by grafting a high density of polyethylene glycol (PEG) chains, 
with a tethered targeting ligand AA. The preparation scheme of 
LCP is illustrated in Figure 1b.
The transmission electron microscope (TEM) photographs 
showed that all drug-loaded LCP-AAs had a spherical shape 
and were monodispersed, with a particle size of around 20 nm 
(Figure 2). The relatively small size of LCPs renders them bet-
ter tumor penetration capability over large size nanoparticles.11 
The zeta potentials of VEGF-LCP-AA, GMP-LCP-AA, and 
(GMP+VEGF)-LCP-AA were 30.2 ± 14.1 mV, 3.4 ± 3.1 mV, and 
10.0 ± 4.0 mV, respectively. The zeta potential of (CMP+Con)-
LCP-AA was identical to the zeta potential of (GMP+VEGF)-
LCP-AA. The encapsulation efficiency (EE%) of VEGF siRNA and 
GMP in LCP-AA was around 55 and 75%, respectively. The EE% 
of VEGF siRNA and GMP in coformulated LCP-AA was almost 
the same as that of the VEGF-LCP-AA or GMP-LCP-AA single 
formulation, which indicates that VEGF siRNA and GMP did not 
interfere with each other in the process of coprecipitation with 
calcium ions within the LCP core.
Drug-loaded LCPs induced VEGF downregulation and 
apoptosis in vivo
Human NSCLC H460 tumor–bearing mice were given three 
daily IV injections of different LCP formulations with a dose of 
50.4 µmol/Kg GMP (19.5 mg/Kg GMP, or 13.2 mg/Kg in terms of 
Gem) and/or 0.2 mg/Kg VEGF siRNA. Twenty-four hours after 
the third injection, mice were killed and tumor lysates were pre-
pared for western blot, and the RNAs in tumors were extracted for 
the RT-PCR measurement of VEGF mRNA levels. VEGF-VEGFR 
signaling in the endothelial cells of tumor blood vessels can be 
prevented by silencing VEGF. PARP is a nuclear protein that per-
forms central roles in the repair of damaged DNA. Cleavage of 
PARP by caspases is considered to be a hallmark of apoptosis.12 
As shown in Figure 3, (GMP+VEGF)-LCP-AA showed signifi-
cant knockdown of VEGF, and stimulated the overexpression of 
cleaved PARP. GMP-LCP-AA activated the cleaved PARP over-
expression and had a partial effect on the VEGF expression level. 
VEGF-LCP-AA clearly reduced the VEGF expression, but had 
limited effect on PARP cleavage. Compared with the control, 
(CMP+Con)-LCP-AA had no measurable effect on the protein 
expression level of VEGF, and was not able to cleave PARP. Tumor 
VEGF mRNA levels in different treatment groups (Figure 3b) 
coincided with the VEGF protein expression levels in the western 
blot analysis (Figure 3a).
Drug-loaded LCPs triggered caspase activation and 
tumor cell apoptosis in vivo
Caspases are proteolytic enzymes and play an important role in 
apoptosis as effector molecules. Among the caspase enzymes, 
caspase-3 and caspase-7 are especially important, and they are 
responsible for the proteolytic cleavage of a large number of sub-
strates during apoptosis.13 Twenty-four hours after three daily 
Figure 2 TEM pictures of (a) VEGF-LCPs, (b) GMP-LCPs, and (c) (GMP+VEGF)-LCPs. Scale bar = 100 nm. GMP, gemcitabine monophosphate; 
LCP, lipid/calcium/phosphate; VEGF, Vascular endothelial growth factor.
a b c
100 nm 100 nm 100 nm
Figure 3 Western blot analysis and VEGF mRNA level after systemic 
treatments. H460 tumor–bearing mice were given three daily IV injec-
tions, and mice were killed 24 hours after the final injection. (a) Tumor 
lysates were prepared for western blot analysis. (b) Tumor VEGF mRNA 
levels in different treatment groups (n = 5) were measured by RT-PCR. 
Data are shown as mean ± SD. *P < 0.05 versus control. AA, anisamide; 
GMP, gemcitabine monophosphate; LCP, lipid/calcium/phosphate; 
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IV injections, caspase-3/7 activity in H460 subcutaneous tumors 
was increased threefold in mice injected with (GMP+VEGF)-
LCP-AA and GMP-LCP-AA and 1.5-fold in mice injected with 
VEGF-LCP-AA, as compared with the control (Figure 4a). 
(CMP+Con)-LCP-AA, free VEGF siRNA, and free GMP dis-
played little caspases elevation (Figure 4a). The results indicated 
that the LCPs greatly improved the in vivo delivery efficiency of 
VEGF siRNA and GMP, and the caspase activation was triggered 
mainly by GMP rather than VEGF siRNA.
We also measured the apoptotic induction in H460 subcuta-
neous tumor tissues using the TdT-mediated dUTP Nick-End 
Labeling (TUNEL) assay. Twenty-four hours after three daily 
IV injections, (GMP+VEGF)-LCP-AA triggered a dramatic 
killing effect, inducing 40% apoptotic cells in tumors. GMP-
LCP-AA and VEGF-LCP-AA led to 22 and 5% apoptotic tumor 
cells, respectively. (CMP+Con)-LCP-AA did not elicit tumor 
cell apoptosis (Figure 4b). The tumor cell apoptotic induction 
of (GMP+VEGF)-LCP-AA was significantly higher than GMP-
LCP-AA and VEGF-LCP-AA, indicating a profound therapeutic 
effect of the combined LCP. GMP-loaded LCPs were more potent 
than VEGF-loaded LCP in terms of tumor cell–killing effect.
Drug-loaded LCPs inhibited the formation of tumor 
vasculature
Next, we evaluated the effect of different LCP formulations on 
the formation of tumor vasculature on H460 subcutaneous 
tumor–bearing mice. We compared two treatment regimens: a 
frequent treatment schedule and an infrequent treatment sched-
ule. The frequent treatment was characterized by daily IV injec-
tions over 3 consecutive days; the mice were killed 24 hours after 
the final injection. The infrequent treatment was characterized 
by IV injections given every other day over 8 days, totaling four 
injections. Mice treated with this regimen were killed 2 days after 
the final injection. Figure 5 shows the results of staining CD31 
antigen, an endothelial cell-specific surface marker. Control 
tumor showed thick, elongated, and disorganized layers of the 
vascular endothelium. (GMP+VEGF)-LCP-AA caused a signifi-
cant reduction in tumor vasculature in both frequent and infre-
quent treatments, indicating an immediate and lasting effect of 
tumor angiogenesis inhibition. VEGF-LCP-AA dramatically 
shut down the tumor vasculature after infrequent treatment, 
but only displayed partial antiangiogenesis effects with sparsely 
dispersed microvessels after frequent treatments, indicating that 
VEGF-LCP-AA needs more time to effectively impair the tumor 
vasculature. It seems that GMP codelivered in the combined 
LCPs sensitized the tumor vasculature for antiangiogenesis 
therapy. Indeed, Gem can induce apoptosis in tumor-associated 
endothelial cells, leading to a decrease in microvessel density 
(MVD).14,15 GMP-LCP-AA caused partial reduction of tumor 
vessel formation after multiple doses. (CMP+Con)-LCP-AA and 
free GMP had little effect on the alteration of the endothelial 
cells compared with the control. The quantitative MVD results 
were shown in Figure 5b,d.
Drug-loaded LCPs triggered tumor cell apoptosis and 
inhibited tumor cell proliferation in vivo
The H460 tumor–bearing mice were given IV injections of differ-
ent LCP formulations every other day for a total of four injections. 
Two days after the final injection, the mice were killed and the 
tumors were sectioned for TUNEL assay, proliferating cell nuclear 
antigen (PCNA) immunohistochemistry and H&E stain. In the 
Figure 4 The caspase activation and induction of apoptosis after 
the systemic administration of different LCPs in H460 xenografts. 
(a) In vivo caspase-3/7 activity in tumors. *P < 0.01, GMP-LCP-AA versus 
control, (GMP+VEGF)-LCP-AA versus control, GMP-LCP-AA versus VEGF-
LCP-AA, and (GMP+VEGF)-LCP-AA versus VEGF-LCP-AA. (b) In vivo tumor 
apoptosis by TUNEL assay. (c) The percentage (%) of apoptotic cells in the 
TUNEL assay. **P < 0.005, VEGF-LCP-AA versus control, GMP-LCP-AA ver-
sus control, (GMP+VEGF)-LCP-AA versus control; *P < 0.01, GMP-LCP-AA 
versus VEGF-LCP-AA, (GMP+VEGF)-LCP-AA versus VEGF-LCP-AA (n = 5 per 
group). AA, anisamide; GMP, gemcitabine monophosphate; LCP, lipid/ 






















































































































1562 www.moleculartherapy.org vol. 21 no. 8 aug. 2013
© The American Society of Gene & Cell Therapy
Codelivery of siRNA and Gemcitabine Monophosphate
TUNEL assay (Figure 6a), (GMP+VEGF)-LCP-AA elicited the 
most effective killing effects and triggered a significant amount 
(~30%) of apoptotic cells in the tumor, more potent than GMP-
LCP-AA which induced 12% apoptotic cells. The results indicates 
antiangiogenesis-induced tumor cell starvation may augment 
the intrinsic cytotoxicity and duration of antitumor effects of the 
coformulated GMP.16 Treatment with VEGF-LCP-AA was less 
efficient than with GMP-LCP-AA, only 3% of tumor cells under-
went apoptosis. (CMP+Con)-LCP-AA and free GMP had limited 
ability to induce apoptosis in tumor cells.
We also evaluated the antiproliferation effect of differ-
ent LCP formulations on H460 tumor–bearing mice. PCNA is 
expressed in the cell nuclei during DNA synthesis and can be 
used as a marker for cell proliferation. As shown in Figure 6c, 
(GMP+VEGF)-LCP-AA significantly decreased the number of 
PCNA positive cells in H460 xenograft tumors. VEGF-LCP-AA 
and GMP-LCP-AA also caused reductions in the proliferation of 
tumor cells. The antiproliferation effect of VEGF-LCP-AA indi-
cates that VEGF not only acts as an endothelial-specific growth 
factor, it can also promote proliferation of tumor cells.17 However, 
(CMP+Con)-LCP-AA and free GMP showed little antiprolif-
erative effect. From this infrequent dosing treatment, we had 
observed additive tumor cell–killing and antiproliferation effects 
of (GMP+VEGF)-LCP-AA compared with the monotherapy of 
GMP-LCP-AA or VEGF-LCP-AA.
Drug-loaded LCPs inhibited mitotic figures in tumors
As shown in the H&E stain (Figure 6e), after infrequent treatment 
in H460 tumor–bearing mice, the control tumor had many mitotic 
figures, showing a high mitotic activity of tumor cells. Some typical 
mitotic figures were shown by arrows in blue. The chromosomes of 
the mitotic figures are visible as tangled, dark-staining threads or 
spots. Counting mitotic figures serves as a tool for differentiating 
benign tumors from malignant ones.18 The control tumor displayed 
various cell morphologies with dark clumped chromatin, indicating 
uncontrollable tumor growth and poor differentiation, otherwise 
known as malignancy. Cellular and nuclear features also correlated 
with proliferative activity, with untreated tumors exhibiting marked 
anisocytosis and anisokaryosis (variation in cell and nuclear size), 
polyploidy, and open vesicular nuclei with dispersed chromatin and 
prominent nucleoli. Tumors that were treated with (GMP+VEGF)-
LCP-AA experienced a dramatic decrease in mitotic figures and 
exhibited more basophilic and uniform nuclei. However, some chro-
mosome condensation remained due to the cytotoxicity induced by 
the combined therapy. The decrease in mitotic figures supported 
the aforementioned PCNA staining, indicating the antiproliferation 
effects of (GMP+VEGF)-LCP-AA partially results from the inhibi-
tion of cell mitosis in tumors. VEGF-LCP-AA and GMP-LCP-AA 
also triggered a decrease in mitotic figures compared with the con-
trol. The mitotic figures of tumors in each group are shown quanti-
tatively in Figure 6f.
Figure 5 (a,b) CD31 immunohistochemistry staining of H460 xenograft tumors after frequent treatment and (c,d) infrequent treatment of different 
LCP formulations. (b) Statistics for frequent treatment: *P < 0.05, **P < 0.005 versus control, ***P < 0.00005 versus control. (d) Statistics for infre-
quent treatment: *P < 0.01, **P < 0.005 versus control, ***P < 0.000001 versus control. (n = 5 per group). GMP, gemcitabine monophosphate; LCP, 
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Tumor growth inhibition
The tumor growth inhibition was evaluated in nude mice bear-
ing H460 subcutaneous tumors. Mice were treated every other 
day for a total of four IV injections with a dose of 50.4 µmol/Kg 
GMP and/or 0.2 mg/Kg VEGF siRNA. As shown in Figure  7, 
(GMP+VEGF)-LCP-AA exhibited the most effective tumor 
growth inhibition; growth was almost completely arrested dur-
ing the combined therapeutic regimen. GMP-LCP-AA also 
suppressed tumor growth effectively, but not as potently as the 
combined nanoparticle treatment. Antiangiogenic monotherapy 
Figure 6 VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-LCP-AA, (CMP+Con)-LCP-AA and free GMP were administered intravenously every other 
day for total four injections. Two days after the last injection, H460 tumor–bearing mice were killed and tumor tissues were sectioned for (a,b) 
TUNEL assay and (c,d) PCNA immunohistochemistry. (e) Mitotic figures (MF) in tumors were evaluated by H&E stain. (b) Statistics of the TUNEL 
assay in H460 xenografts: *P < 0.005, VEGF-LCP-AA versus control, GMP-LCP-AA versus control, VEGF-LCP-AA versus GMP-LCP-AA, VEGF-LCP-AA 
versus (GMP+VEGF)-LCP-AA, GMP-LCP-AA versus (GMP+VEGF)-LCP-AA; **P < 0.001, (GMP+VEGF)-LCP-AA versus control. (d) Statistics of the PCNA 
immunohistochemistry in H460 xenografts: *P < 0.05, VEGF-LCP-AA versus control, GMP-LCP-AA versus control, (GMP+VEGF)-LCP-AA versus VEGF-
LCP-AA, (GMP+VEGF)-LCP-AA versus GMP-LCP-AA; **P < 0.01, (GMP+VEGF)-LCP-AA versus control. (f) Statistics of mitotic figures in tumors: *P < 
0.001, VEGF-LCP-AA versus control, GMP-LCP-AA versus control; **P < 0.0001, (GMP+VEGF)-LCP-AA versus control. (n = 5 per group). AA, anisamide; 
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with VEGF-LCP-AA was not sufficient to obtain long-term tumor 
suppression. VEGF-LCP-AA stabilized the tumor growth at early 
stages of treatment, but unfortunately, was associated with insuffi-
cient anticancer activity and tumor progression at later stages. The 
(CMP+Con)-LCP-AA and free GMP had little effect on tumor 
growth inhibition compared with the control. At the treatment 
end point, representative tumors in each treatment group were 
harvested (Figure 7b) for visual comparison. Tumors treated with 
(GMP+VEGF)-LCP-AA were smaller than tumors in other treat-
ment groups. Thus, the combined treatment with (GMP+VEGF)-
LCP-AA was significantly more effective than treatment with 
GMP-LCP-AA and VEGF-LCP-AA individually.
We further tested the combination therapy in murine ortho-
topic models of human NSCLC that closely recapitulate the 
clinical pattern and progression of lung cancer in humans using 
A549 NSCLC cell lines. Increased visible lung surface nodules 
were indicative of increased tumor burden in orthotropic tumor 
model. As shown in the H&E histopathology analysis (Figure 7c), 
the lung of untreated mice revealed some neoplastic nodules scat-
tering in the parenchyma of the lung lobe and some tumor mass 
adhering to the periphery of the lung or attached in between the 
airway. Some orthotopic tumor nodules displayed a massive and 
contiguous invasion into the surrounding alveolar wall and lung 
alveoli, and necrotic zones can be observed in the central region 
of some tumors. Comparing with the untreated mice, mice treated 
with VEGF-LCP-AA and GMP-LCP-AA displayed a 50% reduc-
tion in size of orthotopically implanted lung tumors; mice treated 
with (GMP+VEGF)-LCP-AA displayed a 70% reduction in size of 
the orthotopic lung tumors.
(GMP+VEGF)-LCP-AA reduced the in vivo toxicity
To test whether GMP and VEGF siRNA–loaded LCPs would induce 
in vivo toxicity, especially hepatic and renal dysfunction after fre-
quent multiple dosing, CD-1 mice were given three daily IV injec-
tions. Twenty-four hours after the final injection, blood samples 
were obtained for hematological analysis and histopathology of 
different organs were evaluated by H&E stain. As shown in Table 1, 
within the normal range, VEGF-LCP-AA induced a relatively high 
level of blood urine nitrogen. GMP-LCP-AA led to higher aspartate 
aminotransferase and alanine aminotransferase compared with the 
Figure 7 Tumor growth inhibition in subcutaneous and orthotopic tumor models of NSCLC. (a) Tumor growth inhibition effects of different 
LCP formulations on H460 tumor–bearing mice. VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-LCP-AA, (CMP+Con)-LCP-AA, and free GMP were admin-
istered intravenously every other day for total four injections. Tumor volumes were measured every other day. Data are mean ± S.D. (n = 6–7 per 
group) Statistics are as follows: *P < 0.01, VEGF-LCP-AA versus control; φP < 0.001, GMP-LCP-AA versus control, (GMP+VEGF)-LCP-AA versus control, 
(GMP+VEGF)-LCP-AA versus VEGF-LCP-AA; ‡P < 0.05, (GMP+VEGF)-LCP-AA versus GMP-LCP-AA.*P < 0.01, (GMP+VEGF)-LCP-AA versus (CMP+Con)-
LCP-AA. (b) Visual observations of the H460 tumor sizes in each treatment group at the end time point. (c) Representative histopathology examina-
tion (H&E staining) of orthotopic lung tumors after LCP treatments. (d) Percentages (%) tumor nodules in the lung in the orthotopic tumor model. 
*P < 0.05, **P < 0.005 versus control. (n = 6 per group). AA, anisamide; CMP, Cytidine monophosphate; GMP, gemcitabine monophosphate; LCP, 
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control. However, treatment with (GMP+VEGF)-LCP-AA allevi-
ated the elevations of blood urine nitrogen, aspartate aminotrans-
ferase, and alanine aminotransferase and kept the parameters of 
kidney and liver functions within the normal range. The admin-
istration of chemotherapy to patients with liver impairment may 
result in complicated safety issues, a treatment regimen using the 
nanoparticles formulated with both GMP and VEGF siRNA can 
help alleviate the potential liver toxicity as well as enhance the 
therapeutic response, compared with treatment with a single agent. 
From the H&E-stained tissue sections of heart, liver, spleen, lung, 
and kidney (Supplementary Figure S1), there were no notice-
able histological changes between the control and (GMP+VEGF)-
LCP-AA treatment group, which showed no evidence of organ 
toxicity. In addition, at the therapeutic dose, no significant immune 
response was elicited after bolus IV administration, as evidenced 
by the production of serum cytokines, including interleukin (IL)-
6, IL-12, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ 
(Figure 8). Taken together, LCP formulations encapsulating che-
motherapeutic agents and therapeutic siRNAs show safety and low 
immunogenicity in vivo.
DISCUSSION
In this study, we report a novel systemic delivery platform consist-
ing of the coformulation of nucleic acid molecules and phosphor-
ylated, small-molecule drugs in a single LCP nanoparticle. GMP 
and VEGF siRNA were coformulated using LCP nanotechnology 
to target two therapeutic pathways of an aggressive human cancer 
malignancy (i.e., NSCLC). Specifically, our delivery system aimed 
to induce apoptosis though GMP chemotherapy and to shut down 
the tumor neovasculature by blocking the VEGF-VEGFR signal-
ing cascade with VEGF RNAi.
Phosphate groups on the molecules can interact with calcium 
in a microemulsion, enabling the encapsulation of GMP and VEGF 
siRNA in the nanoparticle system containing a calcium phosphate 
precipitate (CaP) core (i.e., LCP). A lipid bilayer surrounds the 
CaP core to allow a high density of DSPE-PEG to be grafted onto 
the surface. The surface modification with PEG helps shield the 
cationic charge of the lipid bilayer and may minimize the inter-
action with circulating blood components to prolong circulation 
time of the particle. The prolonged circulation half-life is a prereq-
uisite for enhanced tumor targeting and increases the probability 
that the LCPs will encounter the “leaky” tumor vasculature and 
be exposed to the enhanced permeability and retention effect.19 
The LCP’s high density PEG and small size allow it to evade the 
reticuloendothelial system surveillance, which promote tumor 
accumulation (Supplementary Figure S2) and decrease toxic-
ity in the liver and kidney. With AA as a tumor-specific targeting 
ligand, LCPs can be more effectively taken up into tumor cells via 
sigma-receptor–mediated endocytosis. In addition, the design of 
the CaP core also promotes endosomal release of the cargo while 
preventing lysosomal degradation of the entrapped VEGF siRNA 
and GMP. When LCPs are delivered into acidic endosomes, the 
CaP core of the LCPs rapidly dissolves to increase the osmotic 
pressure in the endosome, eventually bursting the endosomes and 
enabling the entrapped GMP and VEGF siRNA to escape (Figure 
1a).20 The cationic lipid, DOTAP, surrounding the LCP core may 
also promote the release of the entrapped cargo by destabilizing 
the anionic endosome membrane.21
Loading Gem derivatives in LCPs can potentially avoid drug 
efflux proteins (e.g., MRP, BCRP) and the deficiency of cellular 
uptake caused by the mutations of nucleoside transporters (e.g., 
ENT1, ENT2, CNT1, CNT3) in the cell membrane. In our previ-
ous study, we have validated that the nucleotide analogue Gem 
triphosphate (GTP)–loaded LCP nanoparticle showed significant 
antitumor efficacy on lung and pancreatic xenograft models.22 We 
later found that comparing with GTP which was synthesized in an 
big organic salt form, GMP (disodium salt form) gave us higher 
Table 1 Serum levels of BUN, creatinine, AST, and ALT after three 










Control 15.0 ± 3.0 0.4 ± 0.1 129.5 ± 2.5 45.0 ± 1.0
VEGF-LCP-AA 33.0 ± 1.0 0.4 158.5 ± 3.5 30.5 ± 8.5
GMP-LCP-AA 11.0 ± 1.0 0.4 ± 0.1 371.5 ± 31.5 81.0 ± 15.0
(GMP+VEGF)-LCP-
AA
15.0 ± 1.0 0.5 213 ± 95.1 35.0 ± 10.0
Reference range    8–33   0.2–0.9   54–298    17–132
Data are mean ± SD (n = 5 per group).
AA, anisamide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
BUN, blood urine nitrogen; GMP, gemcitabine monophosphate; LCP, lipid/
calcium/phosphate; VEGF, Vascular endothelial growth factor.
Figure 8 Immunotoxicity analysis on normal mice. Mouse serum 
was collected (a) 4 hours and (b) 24 hours after bolus IV administra-
tion of different LCPs at the therapeutic dose. Interleukin (IL)-6, IL-12, 
tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured 
by ELISA. Data = mean ± SD (n = 5 per group). AA, anisamide; CMP, 
Cytidine monophosphate; GMP, gemcitabine monophosphate; LCP, 
lipid/ calcium/phosphate; VEGF, Vascular endothelial growth factor.
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EE% and drug loading, such that similar antitumor efficacy was 
attained. So, GMP was used in the current study. The monophos-
phate modification on GMP allows it to bypass the first rate-lim-
iting phosphorylation step, greatly increasing the conversion rate 
to biologically active Gem triphosphate derivatives. On the other 
hand, the downregulation of VEGF expression in tumors leads to 
blockage of the sequential survival signaling initiated by dimer-
ization and autophosphorylation of VEGFR molecules. Blocking 
VEGF/VEGFR signaling by downregulating VEGF potently 
inhibits aberrant angiogenesis (Figure 1a). In addition, LCPs 
can potentially protect VEGF siRNA and GMP from enzymatic 
degradation (i.e., nuclease and deoxycytidine deaminase, respec-
tively) and renal clearance in vivo.
This study indicates that combining antiangiogenesis 
treatment with chemotherapy through systemic administra-
tions of LCP nanoparticles containing both VEGF siRNA and 
phosphorylated Gem results in an additive antitumor effect. 
The codelivered VEGF siRNA that can damage existing blood 
vessels in tumors might influence response to the concurrent 
chemotherapy. Combination therapies are most likely suc-
cessful because damaging the established tumor endothelium 
has been shown to increase vessel permeability and facili-
tate the delivery of subsequently administered LCPs and the 
coformulated GMP.23 The significant knockdown of the pro-
angiogenic protein, VEGF, caused by the systemic administra-
tions of (GMP+VEGF)-LCP-AA illustrates that this treatment 
regime can lead to decreased tumor angiogenesis (Figure 3). 
Furthermore, MVD is reduced through the reduction of VEGF/
VEGFR interactions and the resulting signaling cascades, as 
indicated by the expression of CD31 antigen in vascular endo-
thelial cells (Figure 5). These effects of (GMP+VEGF)-LCP-AA 
modify the tumor microenvironment to potentiate the deliv-
ery of the chemodrug. GMP entrapped in the combined LCP 
subsequently inhibits the prosurvival program as evidenced by 
elevated PARP cleavage and caspase activation (Figures 3a and 
4a), significant induction of tumor cell apoptosis and reduction 
of tumor cell proliferation (Figures 4b and 6).
The advantages of nanoparticles containing multiple drugs 
are that they can offer the unique features of vehicle uniformity, 
ratiometric drug loading and temporal drug release, while main-
taining the ability to unify the pharmacokinetics of different 
drugs they encapsulate. These nanoparticles are thereby able to 
simultaneously deliver multiple gene- and/or chemotherapeu-
tic agents to the target site.24 We have done some preliminary 
work on the comparison of (GMP+VEGF)-LCP-AA and the 
coadministered mixture of GMP-LCP-AA and VEGF-LCP-AA 
on the antitumor therapeutic response. The results indicated the 
combined (GMP+VEGF)-LCP-AA had more potency in induc-
ing cell-killing effects compared with the administration of sep-
arate LCPs loaded with each individual agent (data not shown). 
The pharmacokinetic profiles and the therapeutic effects of the 
drug loading ratio are now under investigation. The strategy 
of coformulating multiple gene therapeutics and phosphory-
lated chemodrugs in a single vector via LCP nanotechnology is 
expected to lead to superior therapeutic improvement in many 
human diseases, and to modulate multiple therapeutic path-
ways simultaneously.
MATERIALS AND METHODS
Materials. GMP disodium salt was synthesized by HDH Pharma (Research 
Triangle Park, NC). VEGF siRNA (target sequence: 5′-ACC UCA CCA 
AGG CCA GCA C-3′) and control siRNA (target sequence: 5′-AAU UCU 
CCG AAC GUG UCA CGU-3′) were synthesized by Sigma-Aldrich (St 
Louis, MO). 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), dioleoylphosphatydic acid (DOPA), and 1,2-distearoryl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol-2000) 
ammonium salt (DSPE-PEG2000) were purchased from Avanti Polar Lipids 
(Alabaster, AL). DSPE-PEG-AA was synthesized in our lab as described 
previously.25 DeadEnd Fluorometric TUNEL assay kits and Apo-ONE 
Homogeneous Caspase-3/7 assay substrates were obtained from Promega 
(Madison, WI). Other chemicals were obtained from Sigma-Aldrich.
Cell culture. H460 human NSCLC cells, originally obtained from 
American Type Culture Collection (ATCC, Manassas, VA), were cultured 
in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin 
(Invitrogen). Cells were cultivated in a humidified incubator at 37 °C and 
5% CO2. Cells were harvested with 0.05% trypsin-EDTA before subculture.
Experimental animals. Female nude mice 6–8 weeks of age were used in 
all studies. To establish the xenograft models, 5 × 106 H460 cells in 100 
µl of phosphate-buffered saline were injected subcutaneously into the 
right flank of mice. Experiments were performed 11 days after the tumor 
implantation. For the orthotopic model, nude mice were anesthetized and 
a 0.5 cm incision was made after skin disinfection. 5 × 106 A549 cells in 40 
µl of Matrigel-PBS medium (v/v = 1:1) were injected via a 28-gauge needle 
about 2 cm up from the bottom of the ribcage via the left dorsal side of 
nude mice. The incision was closed with a surgery clamp. All animals were 
maintained at a surgical plane of anesthesia during the procedure. The 
mice in control group were untreated mice with no injections. All work 
performed on animals was approved by the Institutional Animal Care and 
Use Committee at University of North Carolina at Chapel Hill.
Preparation of VEGF-LCP-AA, GMP-LCP-AA, and (GMP+VEGF)-LCP-AA. 
LCP cores were prepared using water-in-oil microemulsions, with the oil 
phase containing cyclohexane/Igepal CO-520 solution (71/29, v/v).26 To 
prepare the VEGF-LCP cores, 48 µg VEGF siRNA was mixed with 600 µl 
2.5 mol/l CaCl2 and added into 20 ml of oil phase, where the other emul-
sion contained 600 µl 12.5 mmol/l Na2HPO4 (pH = 9.0). The GMP-LCP 
core was formulated using 180 µl of 60 mmol/l GMP mixed with 12.5 
mmol/l Na2HPO4 (pH = 9.0) (final concentration) to reach a total volume 
of 600 µl. This solution was then added into 20 ml of oil phase. A 600 µl 
2.5 mol/l CaCl2 was added to a separate the 20 ml oil phase. To prepare 
the (GMP+VEGF)-LCP core, the phosphate phase met the same specifica-
tions outlined in the preparation of the GMP-LCP core. The calcium phase 
contained 600 µl of 2.5 mol/l CaCl2 mixed with 48 µg of VEGF siRNA. 
A 400 µl of 20 mmol/l DOPA in chloroform was added to the phosphate 
phase of the GMP-LCP and (GMP+VEGF)-LCP, whereas only 200 µl of 20 
mmol/l DOPA was added to the phosphate phase during the preparation 
of the VEGF-LCP.
The two separate microemulsions were then mixed. After stirring 
for 5 minutes, another 400 µl of 20 mmol/l DOPA was added into the 
emulsion of GMP-LCP and (GMP+VEGF)-LCP; for VEGF-LCP, 200 µl 
of 20 mmol/l DOPA was added. The emulsion was allowed to continually 
stir for another 20 minutes before 40 ml of absolute ethanol was added. 
The ethanol emulsion mixture was centrifuged at 10,000g for 15 minutes 
to pellet the LCP core and the supernatant was then discarded. The LCP 
core was washed twice with absolute ethanol and dried under N2. The LCP 
core pellets were suspended in 2 ml chloroform and stored in a glass vial 
at −20 °C for further use.
To prepare the final VEGF-LCP-AA, GMP-LCP-AA, and 
(GMP+VEGF)-LCP-AA with outer lipid outing, 330 µl LCP core in 
chloroform was mixed with 38.7 µl of 10 mg/ml Cholesterol, 28 µl of 
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25 mg/ml DOTAP, 76.8 µl of 25 mg/ml DSPE-PEG, and 19.2 µl of 25 mg/
ml DSPE-PEG-AA. After evaporating the chloroform, the residual 
lipids were dissolved in 30 µl THF followed by 50 µl absolute ethanol, 
and then suspended in 160 µl water. After brief sonication, the solution 
was dialyzed in distilled water to remove the THF and ethanol. The 
preparation procedure of (CMP+Con)-LCP-AA was identical to that 
of (GMP+VEGF)-LCP-AA, except that GMP and VEGF siRNA were 
replaced by equal molar amount of CMP and control siRNA.
Characterization of VEGF-LCP-AA, GMP-LCP-AA, and (GMP+VEGF)-
LCP-AA. The particle size and zeta potential of LCPs were determined 
by dynamic light scattering using a Malvern ZetaSizer Nano series 
(Westborough, MA). The EE% of GMP or siRNA was measured after lys-
ing the LCPs with a THF/1 mol/l HCl (v/v = 70/30) solution. GMP EE% 
was measured using a UV spectrophotometer (Beckman Coulter, Brea, 
CA; DU 800 spectrophotometer) at a wavelength of 275 nm. The EE% 
of siRNA was measured by mixing a small amount of Texas-red–labeled 
siRNA with VEGF siRNA in LCP cores, and the fluorescence intensity 
of Texas-red was detected at the wavelength of Ex = 589 nm and Em = 
615 nm. TEM images of LCP formulations were acquired through the use 
of JEOL 100CX II TEM (Tokyo, Japan). Briefly, 4 µl of LCP solution was 
dropped onto a 300 mesh carbon coated copper grid (Ted Pella, Redding, 
CA) for 2 minutes. Excess fluid was then removed with filter paper, and the 
copper grid was dried before observation using the TEM.27
Western blot and RT-PCR analysis. Twenty-four hours after the third 
injection, H460 tumor–bearing mice were killed and tumor lysates were 
prepared with radioimmunoprecipitation assay buffer, supplemented 
with a protease inhibitor cocktail (Promega). Protein concentrations were 
determined using a BCA assay kit (Pierce Biotechnology, Rockford, IL) 
following the manufacturer’s recommendations. A 40 µg of protein per 
lane was separated by 4–12% SDS-PAGE electrophoresis (Invitrogen) 
before being transferred into polyvinylidenedifluoride membranes. The 
membranes were blocked for 1 hour with 5% silk milk at room tempera-
ture and then incubated with rabbit polyclonal VEGF antibody and mouse 
monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) antibody (1:500 
dilution; Santa Cruz Biotechnology) overnight at 4 °C. β-actin antibodies 
(1:4,000 dilution; Santa Cruz Biotechnology) served as the loading control. 
The membranes were washed three times and then incubated with sec-
ondary antibodies (1:4,000 dilution; Santa Cruz Biotechnology) at room 
temperature for 1 hour. Finally, the membranes were washed four times 
and developed by an enhanced chemiluminescence system according to 
the manufacturer’s instructions (Thermo Scientific, Milford, MA).
RNAs in tumors were extracted with an RNeasy Mini Kit (Qiagen, 
Valencia, CA). The PCR primers and their fluorogenic probes for the target 
genes were designed by using the computer program Primer Express (PE 
Biosystems, Foster City, CA). The primer sequences for human VEGF 
were: forward, 5′-TCC AAC ATC ACC ATG CAG ATT-3′; reverse, 5′-
GCA TTC ACA TTT GTT GTG CTG T-3′. The primer sequences for 
human β-action were: forward, 5′-GGT CAT CAC CAT TGG CAA TG-3′; 
reverse, 5′-TAG TTT CGT GGA TGC CAC AG-3′. A reporter dye (FAM 
for the target RNA and TET for the β-action control) of each fluorescent 
probe was covalently attached at its 5′ end and a quencher dye (TAMRA) 
was attached at its 3′ end. The probes were purified in the PolyPak II 
cartridge (Glen Research, Sterling, VA) following the manufacturer’s 
instructions. RT-PCR amplifications were performed in a 96-well plate 
in the ABI Prism 7700 sequence detector system in a total volume of 30 
µl, including 10 µl RNA sample and 20 µl of a reaction mixture made 
by following the manufacturer’s instructions (PE Biosystems). Each 
RT-PCR amplification was performed in duplicate: 30 minutes at 48 °C 
for the RT reaction, then 10 minutes at 94 °C, followed by a total of 40 
temperature cycles (15 seconds at 94 °C and 1 minutes at 60 °C).28 During 
the amplification, the fluorescence of FAM (or TET), TAMRA, and ROX 
(a passive reference dye) was measured by the 7700 sequence detector in 
each well of the 96-well plate. The numbers of copies of the PCR template 
in the starting sample were calculated by using the Sequence Detector 
Software incorporated in the ABI Prism 7700 Sequence Detector System 
(Applied Biosystems, Foster City, CA).28
Caspase activation. Twenty-four hours after three daily IV injections, 
40 µg protein of each tumor lysate was used to detect caspase-3/7 activity 
in tumors according to the manufacturer’s instructions (Invitrogen, New 
York, NY). Briefly, 25 µl sample solution containing 40 µg of protein was 
added to a 96-well plate, and 25 µl caspase-3/7 reagent was added to each 
sample well. The contents of the wells were gently mixed at 400 rpm for at 
least 1 hour at room temperature. Their fluorescence was measured using 
a microplate reader at a wavelength of Ex = 485 nm and Em = 535 nm. 
The fluorescence intensity of treatment groups was normalized to that of 
the control group to indicate the extent of caspase activation.
TUNEL assay. After predetermined dosing schedule, H460 tumor–bear-
ing mice were killed and tumors were fixed in 10% formalin for 24 hours 
before embedded in paraffin and sectioned at a thickness of 5 µm. The 
TUNEL staining was performed as recommended by the manufacturer 
(Promega). Then DAPI mounting medium was dropped on the sections 
for nucleus staining. Images of TUNEL-stained tumor sections were cap-
tured with a fluorescence microscope (Nikon, Tokyo, Japan). The percent-
age of apoptotic cells was obtained by dividing the number of apoptotic 
cells (TUNEL positive cells shown as green dots) from the number of total 
cells (blue nuclei stained by DAPI, data not shown) in each microscopic 
field, and 10 representative microscopic fields were randomly selected in 
each treatment group for this analysis.
Immunohistochemistry. Paraffin-embedded tumor sections were obtained 
as mentioned above. The CD31 (1:50 dilution, Abcam, Cambridge, MA) 
and PCNA (1:200 dilution, Santa Cruz Biotechnology) immunohisto-
chemistry was performed using the HRP/DAB detection IHC kit as rec-
ommended by the manufacturer (Abcam). Immunostaining images were 
observed under a light microscope (Nikon). The percentage of prolifera-
tion cells was obtained by dividing the number of PCNA positive cells 
(shown as brown dots) from the number of total cells (blue nuclei stained 
by hematoxylin) in each microscopic field. MVD was evaluated by count-
ing CD31 positive staining vessels in each microscopic field. At least 10 
representative microscopic fields were randomly selected in each treat-
ment group for counting.
Tumor growth inhibition. Tumor growth inhibition of the nanoparticles 
system was evaluated in an H460 subcutaneous xenograft mouse model. 
When the tumor volumes reached about 150–200 mm,3 the mice were 
randomly assigned into six treatment groups (n = 6–7), and intrave-
nously injected different LCPs, including VEGF-LCP-AA, GMP-LCP-AA, 
(GMP+VEGF)-LCP-AA, (CMP+Con)-LCP-AA, and free GMP. The IV 
injections were performed every other day for a total of four injections 
with a dose of 50.4 µmol/Kg GMP and/or 0.2 mg/Kg VEGF siRNA. Tumor 
sizes were measured every other day with calipers across their two per-
pendicular diameters, and the tumor volume was calculated using the fol-
lowing formula: V = 0.5 × (W2 × L), where V = tumor volume, W = the 
smaller perpendicular diameter and L = the larger perpendicular diameter. 
Two days after the final injection, the mice were killed and the tumors were 
stripped off. Some tumors were fixed in 10% formalin and cut into par-
affin-embedded tissue sections for TUNEL assay, immunohistochemistry 
analysis and an H&E stain. Other tumors were arranged and the photo-
graphs of tumors were taken as a visual comparison of the representative 
tumor sizes in each treatment group.
Four weeks after the orthotopic lung tumor implantation, mice were 
randomly assigned into 6 treatment groups (n = 6), and intravenously 
injected VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-LCP-AA, 
(CMP+Con)-LCP-AA, and free GMP twice per week (once every 3 days) 
over 3 weeks, with a dose of 50.4 µmol/Kg GMP and/or 0.2 mg/Kg VEGF 
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siRNA. Mice were killed 1 week after the final injection. Lung tissues were 
fixed in 10% formalin and embedded in paraffin for histological analysis.
In vivo toxicity. Twenty-four hours after three daily IV injections, blood 
was drawn from the venous plexus of the eyes of the mice. Blood sam-
ples were immediately centrifuged at 3,000g for 5 minutes at 4 °C, and 
the supernatant blood serums were collected for hematological analysis. 
Blood urine nitrogen, creatinine, aspartate aminotransferase, and alanine 
aminotransferase values were recorded, as indications of hepatic and renal 
functions. Organs (heart, liver, spleen, lung, and kidney) of mice in differ-
ent treatment groups were fixed and sectioned for H&E staining. Images 
were collected using a Nikon light microscope (Nikon). For immunotox-
icity experiment, mice were given one IV injection of different LCP for-
mulations, and 24 hours later, the cytokines in serum were determined by 
using enzyme-linked immunosorbent assay kits for IL-6, IL-12, TNF-α, 
and IFN-γ (BD Biosciences, San Diego, CA).
Statistical analysis. Results were expressed as a mean ± SD. Student’s 
t-tests were used to evaluate statistical significance. A result of P < 0.05 was 
considered to be statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. Histopathology of different organs evaluated by H&E 
stain.
Figure S2. Tumor uptake of NBD-labeled (GMP+VEGF)-LCP-AA in 
H460 tumor–bearing mice.
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